Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia
NCT ID: NCT06326359
Last Updated: 2024-03-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
40 participants
INTERVENTIONAL
2024-03-31
2026-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison Between Platelet Rich Plasma and Nanofat as an Adjuvant Therapy in HairTransplantation
NCT07287579
Efficacy of Stromal Vascular Fraction Versus Platelet Rich Plasma in Treatment of Androgenitic Alopecia
NCT06558565
A Study to Determine the Safety and Efficacy of Autologous Human Platelet Lysate for Treatment of Androgenetic Alopecia
NCT01643629
Efficacy/ Safety of DNN.22.17.036 in Male Patients With Pattern Hair Loss
NCT06355856
The Effectiveness of Allogenic Mesenchymal Stem Cells Therapy on Hair Regrowth in Androgenetic Alopecia.
NCT06764329
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Group B(20): will be injected with 2 session of Platelet rich plasma 3weeks interval at site of fat harvesting and will be followed 1 month later with fat aspiration from site where Platelet rich plasma was previously injected and this fat will undergo fat processing and stromal vascular fraction extraction followed by 2 session of stromal vascular fraction injection at scalp 1month interval .
Patients at both groups will receive topical and systemic antibiotics after stromal vascular fraction injection .
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
autologous stromal vascular fraction derived from denovo
autologous stromal vascular fraction derived from denovo in male androgenic alopecia
autologous stromal vascular fraction
autologous stromal vascular fraction injection as 2 sessions with 1 month interval at arm 1 arm 2: will receive 2 sessions of PRP with 3 weeks interval followed by stromal vascular fraction injection as 2 sessions with 1 month interval
autologous stromal vascular fraction after platelet rich plasma enhanced donner site
autologous stromal vascular fraction after platelet rich plasma enhanced donner site in male androgenic alopecia
autologous stromal vascular fraction
autologous stromal vascular fraction injection as 2 sessions with 1 month interval at arm 1 arm 2: will receive 2 sessions of PRP with 3 weeks interval followed by stromal vascular fraction injection as 2 sessions with 1 month interval
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
autologous stromal vascular fraction
autologous stromal vascular fraction injection as 2 sessions with 1 month interval at arm 1 arm 2: will receive 2 sessions of PRP with 3 weeks interval followed by stromal vascular fraction injection as 2 sessions with 1 month interval
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
Any other cutaneous disease as patients suffering from dermatological condition or a significant scarring in the treatment area.
Any systemic disease as autoimmune disorders , cardiac hepatic and renal patients.
patients who received minoxidil or any other oral, topical medications (including herbal medications) or injection procedures for the treatment of hair loss within 6 months prior to the study, or finasteride or dutasteride within 12 months of the study
18 Years
55 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dina Ahmed Mahmoud
assistant lecturer
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
reham E Elsharkawy, Professor
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med-24-02-03MD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.